PD13-10 THE PREVALENCE OF CARDIOVASCULAR DISEASE AND ITS RISK FACTORS AMONG PROSTATE CANCER PATIENTS TREATED WITH AND WITHOUT ANDROGEN DEPRIVATION

Abstract

You have accessJournal of UrologyProstate Cancer: Epidemiology & Natural History I (PD13)1 Apr 2020PD13-10 THE PREVALENCE OF CARDIOVASCULAR DISEASE AND ITS RISK FACTORS AMONG PROSTATE CANCER PATIENTS TREATED WITH AND WITHOUT ANDROGEN DEPRIVATION Jehonathan Pinthus*, Bobby Shayegan, Robert Siemens, Laurence Klotz, Patrick Luke, Tamim Niazi, Vincent Fradet, Yves Fradet, Emmanuelle Duceppe, Luke Lavallee, Negareh Mousavi, Robert Hamilton, Ian Brown, Joseph Chin, Darin Gopaul, Darin Gopaul, Philippe Violette, Margot Davis, Sarah Karampatos, Rajibul Mian, and Darryl Leong Jehonathan Pinthus*Jehonathan Pinthus* More articles by this author , Bobby ShayeganBobby Shayegan More articles by this author , Robert SiemensRobert Siemens More articles by this author , Laurence KlotzLaurence Klotz More articles by this author , Patrick LukePatrick Luke More articles by this author , Tamim NiaziTamim Niazi More articles by this author , Vincent FradetVincent Fradet More articles by this author , Yves FradetYves Fradet More articles by this author , Emmanuelle DuceppeEmmanuelle Duceppe More articles by this author , Luke LavalleeLuke Lavallee More articles by this author , Negareh MousaviNegareh Mousavi More articles by this author , Robert HamiltonRobert Hamilton More articles by this author , Ian BrownIan Brown More articles by this author , Joseph ChinJoseph Chin More articles by this author , Darin GopaulDarin Gopaul More articles by this author , Darin GopaulDarin Gopaul More articles by this author , Philippe ViolettePhilippe Violette More articles by this author , Margot DavisMargot Davis More articles by this author , Sarah KarampatosSarah Karampatos More articles by this author , Rajibul MianRajibul Mian More articles by this author , and Darryl LeongDarryl Leong More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000000847.010AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Cardiovascular disease (CVD) is the second most common cause of death in prostate cancer (PC) patients, yet the prevalence of CVD and its risk factors have been incompletely described in this population. Androgen deprivation therapy (ADT) is a risk factor for CVD. The objectives of this study were to describe the CVD characteristics and risk factors in PC patients and the relationship between CVD risk and how ADT is used in real-world practice. METHODS: RADICAL-PC (Role of Androgen Deprivation Therapy in CArdiovascular Disease – A Longitudinal Prostate Cancer Study) is an ongoing prospective cohort study. We recruited 2395 consecutive men (mean age 68 years) with newly diagnosed PC or with a plan to prescribe ADT for the first time. Cardiovascular risk was estimated by calculating Framingham risk scores. A Framingham score >17 (corresponding with a predicted 10-year CVD risk of >30%) was considered high-risk. Multivariable logistic regression was performed with ADT use as the outcome variable and CVD risk factors as the exposures of interest. RESULTS: The prevalence of known CVD for the entire cohort was 22% and 35% had a Framingham risk score >17. Most participants (58%) were current or former smokers; 16% had diabetes; 45% had hypertension and 23% had high blood pressure but had not received a diagnosis of hypertension; 31% were obese (BMI ≥30kg/m2); 24% had low levels of physical activity. There was a positive relationship between each major cardiovascular risk factor and the use of ADT. However, after adjustment for age, education, alcohol use, BMI and time from PC diagnosis to eligibility assessment, these associations were significantly attenuated. Participants in whom ADT was planned had higher Framingham risk scores than those not intending to receive ADT. This risk was abolished after adjustment for confounders. CONCLUSIONS: One in three men with PC is at high cardiovascular risk. Men receiving ADT are a priori at higher CVD risk than PC patients whose treatment strategy does not include ADT. These differences are explained by confounding factors. Source of Funding: Prostate Cancer CanadaHamilton Health Sciences Strategic Research Initiative Heart and Stroke Foundation of Canada © 2020 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 203Issue Supplement 4April 2020Page: e270-e270 Advertisement Copyright & Permissions© 2020 by American Urological Association Education and Research, Inc.MetricsAuthor Information Jehonathan Pinthus* More articles by this author Bobby Shayegan More articles by this author Robert Siemens More articles by this author Laurence Klotz More articles by this author Patrick Luke More articles by this author Tamim Niazi More articles by this author Vincent Fradet More articles by this author Yves Fradet More articles by this author Emmanuelle Duceppe More articles by this author Luke Lavallee More articles by this author Negareh Mousavi More articles by this author Robert Hamilton More articles by this author Ian Brown More articles by this author Joseph Chin More articles by this author Darin Gopaul More articles by this author Darin Gopaul More articles by this author Philippe Violette More articles by this author Margot Davis More articles by this author Sarah Karampatos More articles by this author Rajibul Mian More articles by this author Darryl Leong More articles by this author Expand All Advertisement PDF downloadLoading ...